![Kuo Lung Huang](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Kuo Lung Huang
Sales & Marketing chez
TaiGen Biotechnology Co., Ltd.
Profil
Kuo Lung Huang's career history includes current and former positions as well as education.
Currently, he is the Senior VP-Product Development & Marketing at TaiGen Biotechnology Co., Ltd. He started this position in 2013.
In the past, he worked as the Director-Sales & Marketing at Takeda Pharmaceutical Co., Ltd. He also held the position of Director-Business Development & Product Management at Merck Sharp & Dohme (I.A.) Corp.
(Taiwan).
Additionally, he worked as a Principal at Novartis (Taiwan) Co., Ltd. Mr. Huang obtained his undergraduate degree from Taipei Medical University.
Postes actifs de Kuo Lung Huang
| Sociétés | Poste | Début |
|---|---|---|
TaiGen Biotechnology Co., Ltd.
 TaiGen Biotechnology Co., Ltd. Pharmaceuticals: MajorHealth Technology Engages in the discovery, development and commercialization of drugs | Sales & Marketing | 01/10/2009 |
Anciens postes connus de Kuo Lung Huang
| Sociétés | Poste | Fin |
|---|---|---|
Novartis (Taiwan) Co., Ltd.
 Novartis (Taiwan) Co., Ltd. Part of Novartis AG, Novartis (Taiwan) Co., Ltd. is a Taiwanese branch that integrates pharmaceuticals and oncology units, offering a portfolio of approved medicines across therapeutic areas such as oncology, cardiovascular, renal and metabolic diseases, immunology, neuroscience, and respiratory health. The company is based in Taipei, Taiwan. The Taiwanese company maintains a drug pipeline featuring therapies like radioligand treatments, immunology agents, and neuroscience drugs, with projects in various clinical phases. Novartis (Taiwan) collaborates with patient communities, healthcare professionals, and partners to innovate treatments, improve access to medicines, and address unmet medical needs. The company also supports clinical trials, managed access programs, and adverse event reporting, and leverages digital technologies to enhance healthcare engagement and patient services. | Corporate Officer/Principal | - |
Merck Sharp & Dohme (I.A.) Corp. (Taiwan) | Corporate Officer/Principal | - |
| TAKEDA PHARMACEUTICAL COMPANY LIMITED | Sales & Marketing | - |
Formation de Kuo Lung Huang
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
22
Relations au 1er degré
5
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 5 |
|---|---|
Takeda Pharmaceutical Co., Ltd.
 Takeda Pharmaceutical Co., Ltd. Pharmaceuticals: MajorHealth Technology Engages in the research, development, manufacturing and marketing of pharmaceutical products | Health Technology |
TaiGen Biotechnology Co., Ltd.
TaiGen Biotechnology Co., Ltd. Pharmaceuticals: MajorHealth Technology Engages in the discovery, development and commercialization of drugs | Health Technology |
Taipei Medical University
 Taipei Medical University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Merck Sharp & Dohme (I.A.) Corp. (Taiwan) | |
Novartis (Taiwan) Co., Ltd.
Novartis (Taiwan) Co., Ltd. Part of Novartis AG, Novartis (Taiwan) Co., Ltd. is a Taiwanese branch that integrates pharmaceuticals and oncology units, offering a portfolio of approved medicines across therapeutic areas such as oncology, cardiovascular, renal and metabolic diseases, immunology, neuroscience, and respiratory health. The company is based in Taipei, Taiwan. The Taiwanese company maintains a drug pipeline featuring therapies like radioligand treatments, immunology agents, and neuroscience drugs, with projects in various clinical phases. Novartis (Taiwan) collaborates with patient communities, healthcare professionals, and partners to innovate treatments, improve access to medicines, and address unmet medical needs. The company also supports clinical trials, managed access programs, and adverse event reporting, and leverages digital technologies to enhance healthcare engagement and patient services. |
